US FDA Inspects Neuland Laboratories Facility, Issues Form 483 with One Observation
Neuland Laboratories Limited has received an observation from the United States Food and Drug Administration (US FDA) following an inspection of its manufacturing unit. The review took place at the company's facility in Gaddapotharam village, Jinnaram, Sangareddy District.
The US FDA inspected Unit 3 of Neuland Laboratories from August 10 to August 14, 2026. Following the conclusion of the inspection, the regulatory body issued a Form 483, which contained one observation related to procedural improvements in water and environmental monitoring.
The specific observation mandates that the company must include new organisms beyond those listed in the United States Pharmacopeia (USP). Neuland Laboratories has confirmed it will submit its response addressing the US FDA within the stipulated timelines.
NEULANDLAB Stock Price Movement
Today, shares of Neuland Laboratories Limited edged higher to close at ₹23320, after the company reported a 0.53% gain in post-market trading. The strong performance was underpinned by trading volume amounting to 83,744 shares as it traded near its peak levels and within the high range of ₹23650.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.